Management of Uncommon EGFR Mutations in NSCLC: Dr. Susan Scott
From Oncology Brothers: Practice-Changing Cancer Discussions · · 17 min
This plays from the publisher's own server. We do not host a copy.
Description
In this episode of the Oncology Brothers podcast, we dived deep into the world of uncommon EGFR mutations in non-small cell lung cancer (NSCLC). Joined by Dr. Susan Scott, a thoracic medical oncologist from the Johns Hopkins School of Medicine, as we explored the intricacies of EGFR exon 20 insertions, the third most common mutation, and other rare mutations such as G719X, S768I, and L861Q.
Key topics discussed include:
- The importance of broad-based next-generation sequencing (NGS) testing for identifying EGFR mutations
- Current treatment options for exon 20 insertions, including the combination of amivantamab and chemotherapy, and the promising data surrounding sunvozertinib
- The challenges and considerations in treating patients with central nervous system (CNS) metastases and the role of systemic treatments versus localized therapies
- Insights into the sequencing of treatments for rare EGFR mutations and the potential of datopotamab deruxtecan (Dato-DXd) in refractory settings
Join us for an informative discussion that sheds light on the evolving landscape of targeted therapies for EGFR-mutated NSCLC.
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o
Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966
Follow us on social media:
• X/Twitter: https://x.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and hit the notification bell for more episodes!
#EGFRmNSCLC, #Exon20Insertion, #G719X, #S768I, #L861Q, #OncologyBrothers
Back to Oncology Brothers: Practice-Changing Cancer Discussions · Report a problem